FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2471082284> ?p ?o ?g. }

• W2471082284 endingPage "128" @default.
• W2471082284 startingPage "128" @default.
• W2471082284 abstract "Introduction: PDE5 inhibitors are the firstline treatment for erectile dysfunction. Although all these drugs share the same mechanism of action, each agent could have different characteristics in terms of selectivity, pharmacokinetics and tolerability profile. Materials and Methods: This manuscript illustrates a project, undertaken by the Italian Society of Urology in order to obtain a “snapshot” of the experience of Italian urologists with the use of PDE5 inhibitors in the clinical practice. This project included a survey, targeting a sample of 136 Italian urologists experienced in the treatment of ED, and the organization of a conference of experts who, based on the findings of the survey, the scientific literature and the clinical experience, would define some recommendations for the use of PDE5 inhibitors in clinical practice with a particular focus on Avanafil, the most recent drug in this class. Results: The following recommendations on the use of Avanafil were issued: 1) In patients who are candidates for the use of Avanafil, it is advisable to use the 200-mg dose from the first administration; 2) When used at the highest dose (200 mg), Avanafil shows a favourable tolerability profile with an efficacy similar to that of other agents; 3) The patient should be instructed to take Avanafil on an empty stomach, i.e., 30-45 minutes before or 2 hours after a meal; 4) The efficacy window of Avanafil is between 30 minutes and 6 hours after dosing, which qualifies this molecule as a new drug with an intermediate duration of action; 5) Avanafil at a dose of 50-100 mg/day may be a therapeutic option in chronic rehabilitation. Conclusions: Among PDE5 inhibitors, Avanafil is a new agent with an intermediate duration of action, characterized by high efficacy and good tolerability even at the highest dose (200 mg)." @default.
• W2471082284 created "2016-07-22" @default.
• W2471082284 creator A5006080772 @default.
• W2471082284 creator A5011235818 @default.
• W2471082284 creator A5033097058 @default.
• W2471082284 creator A5042911985 @default.
• W2471082284 date "2016-07-04" @default.
• W2471082284 modified "2023-10-17" @default.
• W2471082284 title "A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice" @default.
• W2471082284 cites W1507601049 @default.
• W2471082284 cites W1559144087 @default.
• W2471082284 cites W1891698889 @default.
• W2471082284 cites W1987026657 @default.
• W2471082284 cites W2014737064 @default.
• W2471082284 cites W2102905860 @default.
• W2471082284 cites W2105308046 @default.
• W2471082284 cites W2112789978 @default.
• W2471082284 cites W2120104785 @default.
• W2471082284 cites W2128056532 @default.
• W2471082284 cites W2133045019 @default.
• W2471082284 cites W2136439241 @default.
• W2471082284 cites W2152150730 @default.
• W2471082284 cites W2194710343 @default.
• W2471082284 cites W2282024057 @default.
• W2471082284 cites W2325112546 @default.
• W2471082284 cites W2464207393 @default.
• W2471082284 doi "https://doi.org/10.4081/aiua.2016.2.128" @default.
• W2471082284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27377089" @default.
• W2471082284 hasPublicationYear "2016" @default.
• W2471082284 type Work @default.
• W2471082284 sameAs 2471082284 @default.
• W2471082284 citedByCount "2" @default.
• W2471082284 countsByYear W24710822842019 @default.
• W2471082284 countsByYear W24710822842021 @default.
• W2471082284 crossrefType "journal-article" @default.
• W2471082284 hasAuthorship W2471082284A5006080772 @default.
• W2471082284 hasAuthorship W2471082284A5011235818 @default.
• W2471082284 hasAuthorship W2471082284A5033097058 @default.
• W2471082284 hasAuthorship W2471082284A5042911985 @default.
• W2471082284 hasBestOaLocation W24710822841 @default.
• W2471082284 hasConcept C126322002 @default.
• W2471082284 hasConcept C197934379 @default.
• W2471082284 hasConcept C2777288759 @default.
• W2471082284 hasConcept C2778375690 @default.
• W2471082284 hasConcept C2779929075 @default.
• W2471082284 hasConcept C2779974597 @default.
• W2471082284 hasConcept C512399662 @default.
• W2471082284 hasConcept C71924100 @default.
• W2471082284 hasConcept C98274493 @default.
• W2471082284 hasConceptScore W2471082284C126322002 @default.
• W2471082284 hasConceptScore W2471082284C197934379 @default.
• W2471082284 hasConceptScore W2471082284C2777288759 @default.
• W2471082284 hasConceptScore W2471082284C2778375690 @default.
• W2471082284 hasConceptScore W2471082284C2779929075 @default.
• W2471082284 hasConceptScore W2471082284C2779974597 @default.
• W2471082284 hasConceptScore W2471082284C512399662 @default.
• W2471082284 hasConceptScore W2471082284C71924100 @default.
• W2471082284 hasConceptScore W2471082284C98274493 @default.
• W2471082284 hasIssue "2" @default.
• W2471082284 hasLocation W24710822841 @default.
• W2471082284 hasLocation W24710822842 @default.
• W2471082284 hasLocation W24710822843 @default.
• W2471082284 hasLocation W24710822844 @default.
• W2471082284 hasOpenAccess W2471082284 @default.
• W2471082284 hasPrimaryLocation W24710822841 @default.
• W2471082284 hasRelatedWork W1988492690 @default.
• W2471082284 hasRelatedWork W2010675100 @default.
• W2471082284 hasRelatedWork W2029413469 @default.
• W2471082284 hasRelatedWork W2039249451 @default.
• W2471082284 hasRelatedWork W2150494864 @default.
• W2471082284 hasRelatedWork W2165094466 @default.
• W2471082284 hasRelatedWork W2363006105 @default.
• W2471082284 hasRelatedWork W2410070599 @default.
• W2471082284 hasRelatedWork W2569534027 @default.
• W2471082284 hasRelatedWork W2907692773 @default.
• W2471082284 hasVolume "88" @default.
• W2471082284 isParatext "false" @default.
• W2471082284 isRetracted "false" @default.
• W2471082284 magId "2471082284" @default.
• W2471082284 workType "article" @default.